Page 7 - Ace2 News Today

Researchers investigated the connecting link between viral genetic variability and clinical heterogeneity of COVID-19 by analyzing the effect of several missense mutations on the ACE2 receptor coding sequence.

Researchers recently investigated the effect of SARS-CoV-2 Omicron variant mutations on the binding of the receptor-binding domain and angiotensin-converting enzyme-2 to study the overall binding profile of the RBD-ACE2 system.

Researchers have been investigating sarbecovirus lineages and the ability of those lineages to evolve the ability to bind ACE2.

Emerging evidence suggests the highly infectious Omicron variant has the ability to escape the protection two vaccine doses offer.

Researchers aimed to understand the relationship between the SARS-CoV-2 receptor-binding domain and both human receptors and therapeutic targets.

Scientists have recently detected and analyzed viral PrDs in the S protein of SARS-CoV-2, which are the novel regulators of virion assembly.

Researchers identify ACE2 as the functional receptor of the two close relatives of MERS-CoV, NeoCoV and PDF-2180-CoV, in bats.

In a study conducted at the Florida International University, USA, scientists have investigated the impact of spike receptor-binding domain (RBD) mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant on its interaction with human angiotensin-converting enzyme 2 (ACE2).

A recent study analyzed the effects of the interaction between SARS-CoV-2 Omicron spike amino acid and the human ACE2 receptor or with human antibodies.

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.